DPT Laboratories, Ltd. and its affiliate DPT Lakewood Inc. recently announced that it reached agreement with Bradley Pharmaceuticals, Inc. to continue a manufacturing agreement for Zonalon™, a topical dermatological preparation, and other products. DPT had been manufacturing Zonalon for Bioglan Pharmaceuticals Company, who was acquired by Bradley on August 10, 2004. Bradley acquired all rights in Zonalon as part of the acquisition and this agreement is to assure a seamless continuation of the manufacturing business.
In addition, Bradley announced that Bradley and DPT were ending all pending litigation between the companies in New Jersey and Texas, which arose out of disputes concerning patents and trade secrets. “Bradley’s past litigation against DPT, and our public statements concerning it, were based on a good faith analysis of the information available to us when we started that case”, states Daniel Glassman, Bradley’s President and CEO. “Our information turned out to be incorrect, and Bradley’s desire to work with DPT on Zonalon testifies to our belief that DPT protects its clients’ confidences and intellectual property, and always has,” said Glassman.
“We are pleased Bradley has publicly acknowledged that their information was incorrect and that DPT takes its clients’ confidentiality very seriously,” says DPT President Paul Johnson. “We will work hard to insure a seamless transition and look forward to a solid future with Bradley,” he adds.
DPT, a DFB Pharmaceuticals, Inc. company, specializes in pharmaceutical development and full service commercial manufacturing of semisolid and liquid, Rx, OTC and biotech products. DPT offerings include semi-solids, liquids, nasal spray, aerosol foam and complex delivery forms, with manufacturing locations in San Antonio, Texas, and Lakewood, New Jersey.
